The Pyroptosis-related Signature Predicts Prognosis and Influences the Tumor Immune Microenvironment in Dedifferentiated Liposarcoma

Overview

Journal Open Med (Wars)

Specialty General Medicine

Date 2024 Jan 15

PMID 38221934

Authors

Wenjing Chen

Jun Cheng

YiQi Cai

Pengfei Wang

Jinji Jin

Affiliations

Soon will be listed here.

Abstract

Background: Dedifferentiated liposarcoma (DDL), a member of malignant mesenchymal tumors, has a high local recurrence rate and poor prognosis. Pyroptosis, a newly discovered programmed cell death, is tightly connected with the progression and outcome of tumor.

Objective: The aim of this study was to explore the role of pyroptosis in DDL.

Methods: We obtained the RNA sequencing data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression databases to identify different pyroptosis-related genes (PRGs) expression pattern. An unsupervised method for clustering based on PRGs was performed. Based on the result of cluster analysis, we researched clinical outcomes and immune microenvironment between clusters. The differentially expressed genes (DEGs) between the two clusters were used to develop a prognosis model by the LASSO Cox regression method, followed by the performance of functional enrichment analysis and single-sample gene set enrichment analysis. All of the above results were validated in the Gene Expression Omnibus (GEO) dataset.

Results: Forty-one differentially expressed PRGs were found between tumor and normal tissues. A consensus clustering analysis based on PRGs was conducted and classified DDL patients into two clusters. Cluster 2 showed a better outcome, higher immune scores, higher immune cells abundances, and higher expression levels in numerous immune checkpoints. DEGs between clusters were identified. A total of 5 gene signatures was built based on the DEGs and divided all DDL patients of the TCGA cohort into low-risk and high-risk groups. The low-risk group indicates greater inflammatory cell infiltration and better outcome. For external validation, the survival difference and immune landscape between the two risk groups of the GEO cohort were also significant. Receiver operating characteristic curves implied that the risk model could exert its function as an outstanding predictor in predicting DDL patients' prognoses.

Conclusion: Our findings revealed the clinical implication and key role in tumor immunity of PRGs in DDL. The risk model is a promising predictive tool that could provide a fundamental basis for future studies and individualized immunotherapy.

References

Samuels B, Chawla S, Somaiah N, Staddon A, Skubitz K, Milhem M . Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer. 2017; 123(23):4640-4647. DOI: 10.1002/cncr.30926. View

Lee A, Thway K, Huang P, Jones R . Clinical and Molecular Spectrum of Liposarcoma. J Clin Oncol. 2017; 36(2):151-159. PMC: 5759315. DOI: 10.1200/JCO.2017.74.9598. View

Runa F, Hamalian S, Meade K, Shisgal P, Gray P, Kelber J . Tumor microenvironment heterogeneity: challenges and opportunities. Curr Mol Biol Rep. 2018; 3(4):218-229. PMC: 5802345. DOI: 10.1007/s40610-017-0073-7. View

Park H, Kim M, Sung M, Lee S, Kim Y, Choi Y . Status of programmed death-ligand 1 expression in sarcomas. J Transl Med. 2018; 16(1):303. PMC: 6219031. DOI: 10.1186/s12967-018-1658-5. View

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D . Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017; 18(1):248-262. DOI: 10.1016/j.celrep.2016.12.019. View

Demetri G, von Mehren M, Jones R, Hensley M, Schuetze S, Staddon A . Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2015; 34(8):786-93. PMC: 5070559. DOI: 10.1200/JCO.2015.62.4734. View

Dunlop M, Dobbins S, Farrington S, Jones A, Palles C, Whiffin N . Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet. 2012; 44(7):770-6. PMC: 4747430. DOI: 10.1038/ng.2293. View

Wang Y, Yin B, Li D, Wang G, Han X, Sun X . GSDME mediates caspase-3-dependent pyroptosis in gastric cancer. Biochem Biophys Res Commun. 2017; 495(1):1418-1425. DOI: 10.1016/j.bbrc.2017.11.156. View

Broz P, Pelegrin P, Shao F . The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2019; 20(3):143-157. DOI: 10.1038/s41577-019-0228-2. View

10.

Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J . The role of pyroptosis in cancer: pro-cancer or pro-"host"?. Cell Death Dis. 2019; 10(9):650. PMC: 6733901. DOI: 10.1038/s41419-019-1883-8. View

11.

Croes L, Op de Beeck K, Pauwels P, Vanden Berghe W, Peeters M, Fransen E . DFNA5 promoter methylation a marker for breast tumorigenesis. Oncotarget. 2017; 8(19):31948-31958. PMC: 5458261. DOI: 10.18632/oncotarget.16654. View

12.

Cervantes-Villagrana R, Albores-Garcia D, Cervantes-Villagrana A, Garcia-Acevez S . Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther. 2020; 5(1):99. PMC: 7303203. DOI: 10.1038/s41392-020-0205-z. View

13.

Chen J, Hang Y, Gao Q, Huang X . Surgical Diagnosis and Treatment of Primary Retroperitoneal Liposarcoma. Front Surg. 2021; 8:672669. PMC: 8211986. DOI: 10.3389/fsurg.2021.672669. View

14.

Wang Y, Gao W, Shi X, Ding J, Liu W, He H . Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017; 547(7661):99-103. DOI: 10.1038/nature22393. View

15.

Thway K, Jones R, Noujaim J, Zaidi S, Miah A, Fisher C . Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies. Adv Anat Pathol. 2015; 23(1):30-40. DOI: 10.1097/PAP.0000000000000101. View

16.

Chen L, Wang L, Tsang N, Ojcius D, Chen C, OuYang C . Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol Med. 2012; 4(12):1276-93. PMC: 3531603. DOI: 10.1002/emmm.201201569. View

17.

Tawbi H, Burgess M, Bolejack V, Van Tine B, Schuetze S, Hu J . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18(11):1493-1501. PMC: 7939029. DOI: 10.1016/S1470-2045(17)30624-1. View

18.

Wang Y, Liu X, Zhao R . Induction of Pyroptosis and Its Implications in Cancer Management. Front Oncol. 2019; 9:971. PMC: 6775187. DOI: 10.3389/fonc.2019.00971. View

19.

DAngelo S, Mahoney M, Van Tine B, Atkins J, Milhem M, Jahagirdar B . Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018; 19(3):416-426. PMC: 6126546. DOI: 10.1016/S1470-2045(18)30006-8. View

20.

Wang F, Li G, Ning J, Chen L, Xu H, Kong X . Alcohol accumulation promotes esophagitis via pyroptosis activation. Int J Biol Sci. 2018; 14(10):1245-1255. PMC: 6097477. DOI: 10.7150/ijbs.24347. View